Recent News for NK - NantKwest, Inc.

Date Title
Jul 10 The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Jul 9 The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Jul 6 Weekly CEO Buys Highlight
Jul 2 The Executive Chairman & CEO of NantKwest, Inc. (NASDAQ:NK), Patrick Soon-Shiong, Just Bought 6.1% More Shares
Jun 30 NantKwest: The Market And The Government Are Missing Out On This Blockbuster
Jun 29 NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 25 The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Jun 25 Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed
Jun 25 NantKwest prices $80M equity offering
Jun 25 NantKwest Announces Pricing of Public Offering of Common Stock
Jun 24 NantKwest readies equity raise
Jun 24 NantKwest Announces Proposed Public Offering of Common Stock
Jun 23 The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
Jun 10 NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
Jun 8 102 Biggest Movers From Friday
Jun 1 Hedge Funds Cashing Out Of Nantkwest Inc (NK)
May 27 NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates
May 27 ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
May 26 NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
May 19 Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths
May 18 FDA signs off in NantKwest IND for cell therapy for ARDS
May 18 NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
May 15 The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
May 14 NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
Apr 29 NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference

Back to the Main NK Page...